Dr. Melinda King ,
-
What FDA’s 2026 GLP-1 safety crackdown means for patients using compounded semaglutide or tirzepatide
FDA’s 2026 GLP-1 crackdown targets compounded or illegally marketed products, not approved brands. Here’s how patients can verify what they’re taking.
-
San Jose Health Brief: Measles Case, Insurance Shifts, and Clinic Access
San Jose, CA – February 27, 2026 – A Santa Clara County measles case prompts vaccine checks, as insurance subsidies shift and clinics reset.
-
Baltimore health brief: H5 avian flu update, storm-related insurance flexibility, opioid-settlement grants, and a hospital recognition
Baltimore, MD – March 2, 2026 – Maryland reported another H5 avian-flu finding as Wellpoint eased storm plan rules and Baltimore awarded opioid grants.
-
Denver Health Brief: Measles exposure alert at DIA, bird flu order, and a patient-privacy update
Denver, CO – February 27, 2026 – Measles exposure alerts at DIA, a bird flu executive order, and Denver Health’s privacy update draw attention.
